| Literature DB >> 31351682 |
Takuya Oda1, Hazumu Nagata2, Yasutaka Nakashima1, Etsuro Nanishi3, Yui Takada1, Manao Nishimura1, Eiji Kubo1, Ken Hatae1, Shouichi Ohga3.
Abstract
Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.Entities:
Keywords: concentration; fever duration; intravenous immunoglobulin; preparation; treatment-related adverse event
Year: 2019 PMID： 31351682 DOI： 10.1016/j.jpeds.2019.06.018
Source DB: PubMed Journal: J Pediatr ISSN： 0022-3476 Impact factor: 4.406